[Iodination conditions of KH901, a tumor-specific oncolytic recombinant adenovirus, and its 125I-labeled compounds biodistribution in animals].
In this research was developed high efficiency method using 125I for directly labeling KH901, a tumor-specific oncolytic recombinant adenovirus, biodistribution of 125I-labeled compound in normal mice was investigated. 125I-KH901 was prepared by N-bromosuccinimide labeling method to find the optimal ratio of labeling response. The compounds were isolated and purified by Sephadex-G10 agarose and the radiochemical purity of compounds was analyzed by paper chromatography. The radioactivity biodistribution in mice was measured at different times after caudal vein injection with 0.1ml 125I-KH901. The labeling yield of 125I-KH901 was 78% and the radiochemical purity was 95% after purification by Sephadex-G10 agarose. Biodistribution revealed that the uptake of 125I-KH901 in liver was higher than in other organs at all time points of the experiment. 125I-KH901 was mainly concentrated in liver, kidneys, spleen and lung. It can be seen that N-bromosuccinimide labeling method is an optimal method with simple steps and high labeling yield in labeling KH901 with 125I. 125I-KH901 has a biodistribution trait which is an advantage to treating liver tumors.
Mi
Yanxia
Y
Department of Nuclear Medicine, West China Hospital, Sichuan University, Chengdu 610041, China.
Li
Yunchun
Y
Long
Yahong
Y
Xie
Peng
P
D000256:Adenoviridae / Q000235:genetics / Q000502:physiology*; D000818:Animals; D004274:DNA, Recombinant / Q000235:genetics*; D005260:Female; D005822:Genetic Vectors / Q000235:genetics; D007457:Iodine Radioisotopes / Q000493:pharmacokinetics*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D050504:Oncolytic Viruses / Q000235:genetics / Q000502:physiology*
D004274:DNA, Recombinant; D007457:Iodine Radioisotopes